A cohort of 253 isolated LR resections from 3211 primary STS resections enabled evaluation of post-recurrence prognosticators with median 5.3-year follow-up and 83 disease-specific deaths. Higher LR ...
A randomized phase 2 maintenance strategy with cabozantinib 60 mg daily for up to 2 years failed to improve 4-month PFS versus placebo in high-grade uterine sarcomas. Median PFS was identical at 3.7 ...
A systematic review finds that diagnostic discordance in bone and soft tissue sarcoma may reduce survival, supporting expert second opinions. STS is a rare cancer that originates as an abnormal growth ...
Evaluation of tyrosinase mRNA as a tumor marker in the blood of melanoma patients. Randomized trial of alternating versus sequential radiotherapy/chemotherapy in ...
Fragmented care - receiving medical treatment at more than one facility - has been associated with both positive and negative outcomes for cancer patients depending on a number of factors such as ...
Fragmented care — receiving medical treatment at more than one facility — has been associated with both positive and negative outcomes for cancer patients depending on a number of factors such as ...
Association of resting mast cell infiltration in the sarcoma microenvironment with overall survival.
Vitamin D serum level as a predictor of response to immunotherapy for non-small cell lung cancer. Effect of genetically engineered Salmonella typhimurium secreting conantokin G on PD-L1 antibody ...
Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the best get-rich-quick stocks to buy according to hedge funds. On February 24, Iovance Biotherapeutics announced positive early data from a pilot ...
Iovance Biotherapeutics reported early pilot trial results for lifileucel in aggressive soft tissue sarcomas. The company plans to start a registrational trial and seek expedited FDA approval based on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results